Saturday 17 October 2026 Export ALGS’s income statement to Excel — free account

Aligos Therapeutics, Inc.

In the quarter to June 2026, revenue grew 2,778.6%, EPS grew 90.9% and free cash flow fell 59.8%, each against the same quarter a year earlier.

4.86 0.53 −9.83%

Follow ALGS

Alert me

Market cap: $33.7M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 3/9
Altman Z: −11.00
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 53.50%

Capital & Financial Ratios $m

Market Cap 33.66

Revenue 31.52

Net Income (75.96)

Free Cash Flow (94.52)

Net Debt (30.42)

Current Ratio 2.19

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.70)

P/S ratio 1.61

P/B ratio 1.59

Past 5Y EPS Growth —

This Y EPS Growth (157.06%)

Next Y EPS Growth 17.79%

Next Y revenue growth 1,546.39%

Next 5Y EPS Growth 0.01%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.91%

10-year low 10-year high

P/B against its own 10 years 65.95%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	136	57	78	30
Receivables	—	—	—	28
Inventory	—	—	—	—
Other	5	5	5	4
	141	62	83	62

	2023	2024	2025	Q'26
Payables	3	3	4	6
ST’ Debt	—	—	—	—
Other	—	—	—	—
	24	22	21	28

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(46.03%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(24.62%)	(19.83%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	28	—	—	—
’25	0	1	1	0	2
’24	1	1	1	1	4
’23	3	7	3	3	16
’22	3	4	4	4	14

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(23)	(25)	—	—	—
’25	(21)	(16)	(24)	(22)	(83)
’24	(23)	(19)	(20)	(18)	(81)
’23	(22)	(14)	(20)	(23)	(79)
’22	(20)	(25)	(17)	(17)	(79)
’21	(30)	(23)	(25)	(37)	(116)
’20	(20)	(18)	(17)	(20)	(74)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(23)	(25)	—	—	—
’25	(21)	(16)	(25)	(22)	(83)
’24	(23)	(19)	(20)	(18)	(81)
’23	(22)	(14)	(20)	(23)	(79)
’22	(21)	(25)	(17)	(17)	(80)
’21	(30)	(23)	(25)	(38)	(117)
’20	(21)	(18)	(17)	(20)	(76)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.21)	(0.14)	—	—	—
’25	4.95	(1.53)	(3.04)	(1.91)	(2.45)
’24	(5.50)	0.75	(3.07)	(13.08)	(20.94)
’23	(13.25)	(10.75)	(10.25)	(5.50)	(34.00)
’22	(21.00)	(11.75)	(11.00)	(12.75)	(56.25)
’21	(18.50)	(19.75)	(19.50)	(22.25)	(80.50)
’20	(189.02)	(184.96)	(274.91)	(27.25)	(271.75)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	320.50	277.75	21.00	13.48	6.76	3.76	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	891.75	937.75	312.00	60.25	44.39	46.80
People
People	Employees	—	—	—	67	74	93	83	66	70	82
	Revenue/emp, $m	—	—	—	0.00	0.00	0.05	0.17	0.24	0.06	0.03
Income, $m
Income, $m	Revenue	—	—	—	—	—	4	14	16	4	2
	Gross margin, %	—	—	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(14)	(52)	(108)	(128)	(96)	(87)	(131)	(24)
	EBT margin, %	—	—	0.00	0.00	0.00	(2,940.79)	(689.87)	(559.50)	(3,317.62)	(1,092.36)
	Net income	—	0	(14)	(52)	(109)	(128)	(96)	(88)	(131)	(24)
	Depreciation	—	—	2	1	4	4	4	3	(1)	(1)
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	2.73	8.14	6.06	0.63	0.22
	Earnings	—	—	(292.22)	(651.02)	(271.75)	(80.50)	(56.25)	(34.00)	(20.94)	(2.45)
	Cash flow	—	—	(126.81)	(582.40)	(185.89)	(72.55)	(46.49)	(30.82)	(12.89)	(8.35)
	Capex	—	—	(52.75)	(34.69)	(5.17)	(0.56)	(0.55)	(0.01)	(0.02)	(0.04)
	Free cash flow	—	—	(179.56)	(617.10)	(191.06)	(73.11)	(47.04)	(30.83)	(12.91)	(8.39)
	Book value	—	—	(288.22)	(808.11)	550.79	115.88	60.84	35.93	(4.62)	5.42
	Shares, m	—	—	0	0	0	2	2	3	6	10
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	108.53	2.89	2.93	63.27	42.14
	P/B	—	—	—	—	—	2.56	0.39	0.49	0.00	1.72
	EV/Sales	—	—	—	—	—	64.80	(6.15)	(5.80)	48.84	6.54
	EV/FCF	—	—	—	—	—	(2.42)	1.07	1.14	(2.38)	(0.17)
Cash, $m
Cash, $m	Operating cash flow	—	—	(6)	(47)	(74)	(116)	(79)	(79)	(81)	(83)
	Capex	—	—	(3)	(3)	(2)	(1)	(1)	0	0	0
	Free cash flow	—	—	(9)	(50)	(76)	(117)	(80)	(79)	(81)	(83)
Balance, $m
Balance, $m	Working capital	—	—	85	106	220	165	100	117	40	62
	Total debt	—	—	0	0	0	0	0	0	0	—
	Net debt	—	—	(91)	(118)	(244)	(191)	(126)	(136)	(57)	(78)
	Shareholders’ equity	—	—	(14)	(65)	220	185	104	92	(29)	54
Returns, %
Returns, %	ROA	—	—	(25.87)	(41.11)	(52.71)	(51.26)	(50.28)	(58.80)	(118.41)	(30.50)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	35.44	132.92	(139.92)	(63.41)	(66.55)	(89.48)	(415.84)	(196.92)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NNVC NanoViricides, Inc.	$35.0M	— (loss-making)	—	—	n/m	−23.94% (below 0%: shrinking)	0.00%	0.00%	Compare
LIANY LianBio Sponsored ADR	$34.2M	0.0×	—	—	n/m	+1,107.59% (above 0%: growing)	0.00%	0.00%	Compare
CRVO CervoMed Inc.	$34.0M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−6.20% (below 0%: shrinking)	100.00%	0.00%	Compare
IRLA Quince Therapeutics, Inc.	$33.8M	— (loss-making)	—	—	n/m	−63.65% (below 0%: shrinking)	0.00%	0.00%	Compare
ALGS Aligos Therapeutics, Inc.	$33.7M	— (loss-making)	— (loss-making)	+2,778.55% (above 0%: growing)	n/m	−59.81% (below 0%: shrinking)	100.00%	(6.80%)
ATNM Actinium Pharmaceuticals, Inc.	$33.3M	3.1×	— (loss-making)	+77,677.78% (above 0%: growing)	n/m	−4.91% (below 0%: shrinking)	100.00%	78.76%	Compare
BCTX BRIACELL THERAP	$32.8M	1.5×	—	—	n/m	+0.21% (above 0%: growing)	0.00%	0.00%	Compare
GNTA Genenta Science S.p.A. Unsponsored ADR	$32.3M	—	—	—	—	+35.94% (above 0%: growing)	0.00%	—	Compare
MGX Metagenomi Therapeutics, Inc.	$31.9M	— (loss-making)	— (loss-making)	−103.02% (below 0%: shrinking)	n/m	+7.98% (above 0%: growing)	100.00%	11,195.72%	Compare
Median of peers	$33.6M	1.5×	—	−99.60%	—	−2.35%	0.00%	0.00%

All 614 Biotechnology stocks →

Aligos Therapeutics, Inc. (ALGS) key facts

Aligos Therapeutics, Inc. (ALGS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ALGS traded at $4.86, a market capitalization of $33.7 million.
Return on equity was −196.9% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −11.00 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.